Literature DB >> 19220151

Omeprazole significantly reduces posaconazole serum trough level.

Jan-Willem C Alffenaar, Sander van Assen, Tjip S van der Werf, Jos G W Kosterink, Donald R A Uges.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19220151     DOI： 10.1086/597110

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  14 in total

1.  Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview.

Authors:  Hans-Peter Lipp
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

2.  Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.

Authors:  J J Vehreschild; C Müller; F Farowski; M J G T Vehreschild; O A Cornely; U Fuhr; K-A Kreuzer; M Hallek; V Kohl
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

3.  Plasma concentrations of posaconazole administered via nasogastric tube in patients in a surgical intensive care unit.

Authors:  Dominic Störzinger; Stephan Borghorst; Stefan Hofer; Cornelius J Busch; Christoph Lichtenstern; Georg Hempel; Markus A Weigand; Torsten Hoppe-Tichy
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

4.  Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations.

Authors:  Piergiorgio Cojutti; Anna Candoni; Erica Simeone; Loretta Franceschi; Renato Fanin; Federico Pea
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

5.  What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice?

Authors:  Federico Pea; Mario Furlanut; Pierluigi Viale
Journal:  Antimicrob Agents Chemother       Date:  2009-08       Impact factor: 5.191

6.  Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome.

Authors:  M Vaes; M Hites; F Cotton; A M Bourguignon; M Csergö; C Rasson; L Ameye; D Bron; F Jacobs; M Aoun
Journal:  Antimicrob Agents Chemother       Date:  2012-10-01       Impact factor: 5.191

Review 7.  Current concepts in antifungal pharmacology.

Authors:  Russell E Lewis
Journal:  Mayo Clin Proc       Date:  2011-08       Impact factor: 7.616

8.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

9.  Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management.

Authors:  Wei Li; Su Zeng; Lu-Shan Yu; Quan Zhou
Journal:  Ther Clin Risk Manag       Date:  2013-05-27       Impact factor: 2.423

10.  Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.

Authors:  Dionissios Neofytos; Edina Avdic; Anna-Pelagia Magiorakos
Journal:  Drug Healthc Patient Saf       Date:  2010-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.